Chronic obstructive pulmonary disease and asthma: mesenchymal stem cells and their extracellular vesicles as potential therapeutic tools

Hossein Abbaszadeh¹, Farzaneh Ghorbani¹, Sanaz Abbaspour-Aghdam¹, Amin Kamrani¹, Hamed Valizadeh², Mehdi Nadiri², Armin Sadeghi², Karim Shamsasenjan¹, Farhad Jadidi-Niaragh³, Leila Roshangar¹* and Majid Ahmadi¹*

Abstract
Chronic lung diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, are one of the most frequent causes of morbidity and mortality in the global. COPD is characterized by progressive loss of lung function through inflammation, apoptosis, and oxidative stress caused by chronic exposure to harmful environmental pollutants. Airway inflammation and epithelial remodeling are also two main characteristics of asthma. In spite of extensive efforts from researchers, there is still a great need for novel therapeutic approaches for treatment of these conditions. Accumulating evidence suggests the potential role of mesenchymal stem cells (MSCs) in treatment of many lung injuries due to their beneficial features including immunomodulation and tissue regeneration. Besides, the therapeutic advantages of MSCs are chiefly related to their paracrine functions such as releasing extracellular vesicles (EVs). EVs comprising exosomes and microvesicles are heterogeneous bilayer membrane structures loaded with various lipids, nucleic acids and proteins. Due to their lower immunogenicity, tumorigenicity, and easier management, EVs have appeared as favorable alternatives to stem cell therapies. Therefore, in this review, we provided an overview on the current understanding of the importance of MSCs and MSC-derived EVs from different sources reported in preclinical and clinical COPD and asthmatic models.

Keywords: Lung diseases, COPD, Emphysema, Asthma, Exosomes, Microvesicles, Regeneration, Mesenchymal stromal cells

Introduction
Chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), have represented an extremely high social burden. COPD is a common and progressive lung condition, associated with irreversible airflow obstruction and airway inflammation which have adverse effects on the patient’s breathing and restrict lung function, measured by total lung capacity and forced expiratory volume (FEV) [1–4]. Furthermore, chronic cough, wheezing, dyspnea, as well as sputum and phlegm are the other common symptoms for COPD [4, 5]. According to the World Health Organization (WHO) prediction, COPD will become the third leading cause of morbidity and mortality across the globe in 2030 [6] and represents a considerable economic burden on the individual and society [7]. Long-term exposure to noxious particles or gases, particularly cigarette smoke (CS),

*Correspondence: lroshangar@yahoo.com; ahmadi.m@tbzmed.ac.ir
1 Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Full list of author information is available at the end of the article.
is the major risk factor for developing COPD [8, 9]. CS exposure induces increased number of neutrophils, lymphocytes, and macrophages and cause inflammation in the small airway and lungs through releasing different pro-inflammatory mediators [8, 10]. Asthma is also a heterogeneous disorder which regularly indicates development of airway obstruction [11, 12]. It is characterized by airway inflammation, bronchospasm and amplified mucus production inside the airways [13, 14].

Current available treatment methods for COPD and asthma such as anti-inflammatory drugs, corticosteroids, long-acting muscarinic antagonists and β2-adrenoceptor agonists may help slow the progression of these disorders but cannot reverse the lung damage or improve the quality of life in these patients [1, 15–17]. Therefore, more research efforts are required to better understand the molecular mechanism of COPD and asthma pathogenesis and development of new therapeutic and diagnostic approaches.

Increasing data have specified that mesenchymal stem cells (MSCs) are great means for cell-based therapy and regenerative medicine because of their multipotent differentiation and self-renewal abilities and immunomodulatory properties, as well as long-term ex vivo proliferation and paracrine effects [18–21]. MSCs have been widely studied in respiratory diseases including COPD, asthma, and idiopathic pulmonary fibrosis, and are powerful candidates for regeneration of lung damages [4, 16, 22–24]. Additionally, it has been proven that the beneficial effects of MSCs are mostly associated with their paracrine factors, especially extracellular vesicles (EVs) [25, 26]. EVs including exosomes, microvesicles (MVs), and microparticles (MPs), and their miRNAs content, have been widely reported as potential therapeutic means for a variety of lung diseases and they also serve as signaling molecules to mediate cell–cell communications, particularly between epithelial cells and lung microenvironment [27–29]. As compared with their parental MSCs, these vesicles represent a better safety profile and can be stored without missing function [30].

Accordingly, in this review, we will summarize current knowledge about the role of MSCs and their EVs, principally exosomes, in treatment of COPD and asthma disorders (Fig. 1 and Fig. 2).

**MSCs and their EVs**

MSCs are multipotent adult stem cells which have become extensively studied during the past 30 years in both preclinical and clinical trials for numerous disorders [31, 32]. They can differentiate into multiple lineages, including osteocytes, adipocytes and chondrocytes and can be found approximately in all postnatal organs such as bone marrow (BM), adipose tissue (AD), human-induced pluripotent stem cells (hi-PSC), Wharton’s Jelly (WJ), human cord blood (hUC), umbilical cord (UCB), and human amniotic membrane (hAM) as well as human placental (hP) and dental follicle [33–35]. In general, these MSCs express surface markers, such as CD105, CD90, and CD73, but not CD34, CD45, CD19, CD11b, CD79a, and CD14 [36–38]. MSCs pose broad anti-inflammatory, immunoregulatory and regenerative features [39–42]. It has been elucidated that EVs secreted from MSCs have key role in mediating biological processes, for example blood coagulation, stem cell differentiation, immunomodulation, and regeneration as well as angiogenesis and etc. [43–45]. EVs are nanosized vesicles that have two main subtypes including exosomes which are sized in 30 to 150 nm in diameter generated from secretion of microvesicular bodies into extracellular space. MVs are other main types of EVs that are sized between 100 to 1000 nm and formed by direct budding from the plasma membrane [32, 46, 47].

**Various MSCs in treatment of COPD and asthma**

As demonstrated in Tables 1 and 2, accumulating studies have recently examined the potential contribution of MSCs derived from different sources including BM, hi-PSCs, WJ, hCB, UC, AD and hAM as well as hP and dental follicle in regeneration and treatment of COPD and asthma, which are discussed in the next parts.

**Bone marrow-MSCs**

**COPD**

In 2016, an in vitro study provided evidence that conditioned media (CM) from BM-MSCs stimulated with pro-inflammatory cytokines such as TNF-α and IL-1β is a potential method to enhance the regeneration of airway epithelial wound in NCI-H292 cells and could be beneficial in COPD treatment which may mainly be mediated by induction of hepatocyte growth factor (HGF) and epidermal growth factor receptor (EGFR) and subsequent activation of the ERK1/2 signaling pathway [48]. Recently, Hong-mei LIU et al. (2015) reported that BM-MSC administration could regenerate lung damage via promoting proliferation of endogenous lung stem cells in COPD mice induced by the CS [49]. Additionally, a recent finding has demonstrated the therapeutic impact of rat BM-MSCs intrapulmonary administrated into the lungs of CS-induced emphysematous rats by downregulation of the cell apoptosis, inflammation and protease expression as well as increase of vascular endothelial growth factor (VEGF) and transforming growth factor-β1 (TGF-β1). Nonetheless, the authors declared that these MSCs did not fully reverse emphysema. Besides, single injection of BM-MSCs to rats was a drawback of this experiment [50]. In another animal study, BM-MSCs ameliorated
l lung damage in acute exacerbation COPD mice model by anti-bacterial effects and relieving inflammation reaction which may be mediated by secretion of TSG-6, inhibition of NF-κB signaling and enhancement of macrophages phagocytosis via paracrine mechanisms [51]. It has also been reported that intrabronchial BM-MSC transplantation relived airway inflammation and emphysema in CS-exposed rat models via regulation of cyclooxygenase-2 (COX-2) and PGE2 synthesis in alveolar macrophages by p38 and ERK MAPK signaling pathways. However, the authors did not elucidate the role of JNK in reduction of COX-2 [52]. Kennelly et al. [53] also revealed that human BM-MSC therapy could protect against COPD and decrease lung injury by significant anti-inflammatory, anti-fibrotic and anti-apoptotic functions which are associated to elevation of hepatocyte growth factor (HGF) in mouse model of COPD. Chen et al. [54] established that intravenous injection of BM-MSCs could alleviate emphysema through differentiating into endothelialocytes, reducing their apoptosis and oxidative stress in rats with overlap syndrome after four weeks. Nonetheless, it is unclear that if multiple administration of undifferentiated BM-MSCs elevate risk of cancer. It has also been indicated that cis-resveratrol (c-RSV)-treated VEGF factor A (VEGFA) expression in heat-shock protein (HSP)-VEGFA- transduced BM-MSCs considerably enhanced the therapeutic impacts in mouse with COPD through downregulation of inflammatory cytokines, elevation of anti-oxidant genes and regeneration of lung cells [55].

Several clinical trials have also been studied the role of BM-MSCs in COPD patients. For instance, in a study conducted by Broekman et al. [56], the therapeutic
potential of autologous BM-MSCs from COPD patients were evaluated. According to the results, these MSCs were phenotypically and functionally comparable to those MSCs from healthy controls and may be suitable choices for COPD treatment. However, they found several differences including IL-6 secretion, adipocyte differentiation and NQO1 expression via Nrf2-ARE pathway. A phase I, prospective open-label trial (NCT01306513) in Netherlands assessed the safety and feasibility of intravenous infusion of two doses of autologous BM-MSCs (1–2 × 10^6 cells/kg) after and prior to one-sided lung volume reduction surgery (LVRS) and a second LVRS procedure, respectively in 10 subjects with severe lung emphysema. All participants showed elevated FEV1 and no adverse effects and fibrotic reactions were observed after one-year follow-up. Nevertheless, lack of a placebo group was the major drawback of this study. Moreover, since endothelial injury is a prominent sign of emphysema, they used just CD31 as endothelial cells marker, however, it is not limited to these cells alone and extra markers are required to investigate this result. Additionally, the trial was not randomized and placebo-controlled and a larger number of patients were needed [57]. Oliveira et al. (2016) conducted a placebo-controlled, nonrandomized phase I clinical study involving 10 patients with severe COPD and aged between 40 to 80 years who recruited from Hospital de Clinicas de Porto Alegre, Brazil (ClinicalTrials.gov identifier: NCT01872624). Five participants bronchoscopically received combined BM-MSC (10^8 cells) therapy with one-way endobronchial valves (EBV) insertion and the remaining 5 patients received saline as the control and monitored up to three months. The results of this study indicated that BM-MSC transplantation appeared to
Table 1: Therapeutic application of various mesenchymal stem cells and their extracellular vesicles in preclinical COPD and asthma models

| Injury  | Study type | type of MSCs                  | Infusion method | Dose of injection | Outcome                                                                                                                                                                                                 | Reference |
|---------|------------|-------------------------------|-----------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| COPD    | NCI-H292 airway epithelial cells | TNF-α and IL-1β-activated BM-MSCs | –               | –                 | Increased airway epithelial wound healing via activation of the epidermal growth factor receptor                                                                                                            | [48]      |
| COPD    | Mice model | BM-MSCs                       | Intravenous     | 4 × 10⁶ cells/mL  | Relieved lung injury through promoting proliferation of endogenous lung stem cells                                                                                                                      | [49]      |
| COPD    | Rat model  | BM-MSCs                       | Intratracheal   | 6 × 10⁶ cells/mL  | Protect cigarette smoke-damaged lung and pulmonary function partly via VEGF–VEGF receptors                                                                                                                | [50]      |
| COPD    | Mice model | BM-MSCs                       | Intravenous     | 4 × 10⁶ cells/mL  | Ameliorate lung injury through anti-inflammatory and anti-bacterial effect                                                                                                                              | [51]      |
| COPD    | Rat model  | BM-MSCs                       | Intratracheal   | 6 × 10⁶ cells/mL  | Alleviated airway inflammation and emphysema through down-regulation of cyclooxygenase-2 via p38 and ERK MAPK pathways                                                                                   | [52]      |
| COPD    | Mice model | BM-MSCs                       | Intravenous     | 5 × 10⁵ cells/mouse | Exerted HGF dependent cytoprotective effects                                                                                                                                                    | [53]      |
| COPD    | Rat model  | BM-MSCs                       | Intravenous     | 2 × 10⁶ cells/rat | Inhibited the progression of emphysema by differentiating into endotheliocytes and suppressing the apoptosis of endotheliocytes and oxidative stress                                                                      | [54]      |
| COPD    | Mice model | HSP-VEGFA-BM-MSCs              | Intravenous     | –                 | Alleviated elastase-induced emphysema                                                                                                                                                    | [55]      |
| Asthma  | Mice model | BM-MSCs                       | Intravenous     | 10⁶ cells/mouse   | Simvastatin and BM-MSCs combination therapy affects serum IgE as well as lung IL-13 and TGFβ levels more than BM-MSCs and simvastatin therapy alone                                                                 | [63]      |
| Asthma  | Mice model | BM-MSCs                       | Intravenous     | 2.5 × 10⁵ cells   | Controlled inflammation, immune-inflammatory factors and mitochondrial related genes, and prevent asthma immune-pathology                                                                       | [64]      |
| Asthma  | Mice model | BM-MSCs AD-MSCs Lung-MSCs      | Intratracheal   | 10⁵ cells/mouse   | Released different mediators and differentially affected airway and lung parenchyma                                                                                                                   | [65]      |
| Asthma  | Rat model  | BM-MSCs                       | Intratracheal   | 2 × 10⁶ cells/rat | CM and especially MSCs ameliorated pathological changes via intratracheal route presumably by targeting ICAM-1 and VCAM-1 in lung tissues                                                                   | [66]      |
| Asthma  | Mice model | BM-MSCs                       | Intraperitoneal  | 10⁶ and 2 × 10⁶ cells | Ameliorated to the airway remodeling and airway inflammation both in the upper and lower airways via the inhibition of Th2 immune response in the murine model of AR                                                                 | [67]      |
| Asthma  | Rat model  | BM-MSCs                       | Intravenous     | –                 | Affected on Th1/Th2 drift, and the Notch1/Jagged1 pathway and may participate in the homing of the BM-MSCs                                                                                                      | [68]      |
| Asthma  | Mice model | BM-MSCs                       | Intravenous     | 2 × 10⁶ cells/mouse | Significantly reduced total cells and eosinophilia and serum OVA-specific IgE concentration and inhibited expressions of Th2 and Th17 cytokines and elevated levels of Treg cytokines                                              | [69]      |
| Asthma  | Mice model | BM-MSCs                       | –               | –                 | Alleviated asthma by inducing polarization of alveolar macrophages                                                                                                                            | [70]      |
| Injury   | Study type  | type of MSCs               | Infusion method | Dose of injection | Outcome                                                                                     | Reference |
|---------|-------------|---------------------------|-----------------|-------------------|---------------------------------------------------------------------------------------------|-----------|
| Asthma  | Mice model  | BM-MSCs                   | retro-orbital   | $10^6$ cells/mouse| Participated in improved outcomes of remodeling by reversing excess collagen deposition and changing hyaluronan levels | [71]      |
| COPD    | Mice model  | ASMG-treated iPSC-MSCs    | Intravenous     | $10^6$ cells/mouse| Alleviated oxidative stress-induced mitochondrial dysfunction in the airways               | [72]      |
| Asthma  | Mice model  | iPSC-MSCs mesenchymoangioblast-MSCs | Intranasal     | $10^6$ cells/mouse| Provided greater protection against experimental chronic allergic airways disease compared with a clinically used corticosteroid | [73]      |
| COPD    | Mice model  | Pioglitazone pretreated WJ-MSCs | Intravenous     | $10^6$ cells/mouse| Produced greater lung regeneration, compared to non-augmented WJ-MSCs, in a mouse emphysema model | [74]      |
| COPD    | Mice model  | WJ-MSCs                   | Intravenous     | $5 \times 10^4$ cells/mouse | They didn't confirm the effects of WJ-MSCs in COPD through this experiment             | [75]      |
| COPD    | Mice model  | HCB-MSCs                  | Intravenous     | $5 \times 10^4$ cells/mouse | Improved the regenerative mechanisms based on the gene expression profile changes          | [76]      |
| Asthma  | Mice model  | HCB-MSCs                  | Intravenous     | $10^5$ cells/mouse| Suppressed severe asthma by directly regulating Th2 cells and type 2 innate lymphoid cells | [77]      |
| Asthma  | Mice model  | AD-MSCs                   | Intravenous     | $2.5 \times 10^7$ cells/Kg | Suppressed AHR and airway inflammation and induced eosinophilic airway inflammation and lung histological changes | [81]      |
| Asthma  | Mice model  | AD-MSCs                   | Intratracheal   | $10^6$ cells/mouse| Alleviated airway inflammation, improved airway remodeling, and relieved AHR             | [17]      |
| Asthma  | Mice model  | AD-MSCs                   | Intravenous     | $10^5$ cells/mouse| Reduced lung inflammation and remodeling while causing immunosuppression                  | [82]      |
| Asthma  | Feline model| AD-MSCs                   | Intravenous     | $2 \times 10^5$, $4 \times 10^5$, $4.7 \times 10^5$ and $10^7$ cells/cat | Had a delayed potential in decreasing airway inflammation, AHR and remodeling               | [83]      |
| Asthma  | Mice model  | HAM-MSC-CM                | Intravenous     | $10^6$ cells/mouse| Reduced inflammatory factors and fibrosis                                                    | [84]      |
| Asthma  | Rat model   | HP-MSCs                   | Intraperitoneal | $10^6$ cells/Kg   | Suppressed airway inflammation in asthmatic rats by modulating Notch signaling             | [85]      |
| Asthma  | In vitro    | HP-MSCs                   | –               | –                 | Reduced the IL-5 level experimentally in children with asthma                              | [86]      |
| Asthma  | Rat model   | HP-MSCs                   | Intravenous     | $1 \times 10^7$ cells/ml | Improved AHR and inflammation by modulating the Th17/Treg balance                        | [87]      |
| Asthma  | In vitro    | DF-MSCs                   | –               | –                 | Down-regulated Th2-mediated immune response in asthmatic patients mononuclear cells       | [88]      |
| COPD    | Mice model  | BM-MSCs and BM-MSC-Exos  | Intraperitoneal | $10^6$ cells | Combination treatment may act against early events caused by CS exposure owing to its anti-inflammatory and other mitochondrial transfer mechanisms | [89]      |
| Asthma  | In vitro    | BM-MSC-Exos               | –               | –                 | Promoted immunosuppression of regulatory T cells                                          | [90]      |
| Injury  | Study type | type of MSCs                  | Infusion method | Dose of injection | Outcome                                                                 | Reference |
|--------|------------|-------------------------------|----------------|-------------------|--------------------------------------------------------------------------|-----------|
| Asthma | Rat model  | BM-MSCs and BM-MSC-Exos      | Intravenous    | $5 \times 10^6$ cells/cat | Reduced airway remodeling in lungs through the Wnt/β-catenin signaling pathway | [91]      |
| Asthma | Mice model | BM-MSC-Exo-miR-188           | –              | –                 | Reduced bronchial smooth muscle cell proliferation in asthma through suppressing the JARID2/Wnt/β-catenin axis | [92]      |
| Asthma | In vitro   | BM-MSC-Exo-miR-146a-5p       | –              | –                 | Inhibited Th2 differentiation via regulating miR-146a-5p/SERPINE2 pathway | [93]      |
| Asthma | Mice model | AD-MSC-EVs                   | Intranasal     | 10 μg             | Alleviated AHR and allergic airway inflammation caused by the induction of Treg expansion | [94]      |
| Asthma | Mice model | AD-MSC-Exo-miR-301a-3p       | –              | –                 | Regulated airway smooth muscle cells by targeting STAT3                  | [95]      |
| Asthma | Mice model | AD-MSC-EVs                   | Jugular        | 37 μg             | Acted differentially on lung mechanics and inflammation in experimental allergic asthma | [96]      |
| Asthma | Mice model | mmu_circ_0001359-modified AD-MSC-Exos | Intravenous | 200 μg | Attenuated airway remodeling by enhancing FoxO1 signaling-mediated M2-like macrophage activation | [97]      |
| Asthma | Mice model | iPSC-MSC- EV-miR-146a-5p     | Intravenous    | 100 μg            | Prevented group 2 innate lymphoid cell-dominant allergic airway inflammation | [98]      |
| Asthma | Mice model | Hypoxic-hUC-MSC-EVs          | Intravenous    | 40 μg             | Attenuated allergic airway inflammation and airway remodeling          | [99]      |
| Asthma | RAW 264.7 cell line | HUC-MSC-Exos   | –              | –                 | Attenuated the inflammation of severe steroid-resistant asthma by reshaping macrophage polarization | [100]     |
| COPD   | Mice model | P-MSC-Exo-MAPPS             | –              | –                 | Enhanced pulmonary function through decreasing serum concentrations of inflammatory cytokines, lung-infiltrated macrophages, neutrophils, and natural killer and antigen-presenting cells and elevated anti-inflammatory IL-10 and (Tregs) | [101]     |
| Asthma | Mice model | hP-MSC-Exos                  | Intranasal     | 50 μg             | Expanded lung IL-10-producing iMs, which may originate from spleen, thus contribute to protection against asthma | [102]     |
be safe and made no remarkable change in frequency of COPD exacerbations, severity of disease and radiological outcomes. Nonetheless, the C-reactive protein (CRP) levels was decreased in days 30 and 90 and quality of life was improved in the BM-MSC-treated group. Short following-up period, low number of participants, and evaluation of inflammatory mediators only in plasma was the major disadvantages of this study [58]. Similarly, treatment of COPD patients with BM-derived mononuclear cells (BM-MCs), heterogeneous pool of cells which contains MSCs, has displayed emerging outcomes. In 2013, one phase I clinical trial has been performed by Universidade Estadual Paulista (UNESP) in Assis, SP, Brazil (ClinicalTrials.gov, NCT01110252). In this study, collected autologous BM-MCs ($10^6$ cells/kg) were intravenously injected to four patients with advanced COPD and followed up for 3 years. No adverse effects were found in these patients and half of them showed an improvement in FEV1. Despite the small sample, these enhancements in pulmonary function could be as result of anti-inflammatory properties of BM-MC therapy [59]. A phase I pilot study has also been designed to determine the allogeneic BM-MSCs effect in treatment of 9 patients with moderate to severe COPD (Australian clinical trials registry no. 12614000731695). BM-MSCs ($2 \times 10^6$ cells/kg) was intravenously infused to the participants twice times and followed up to 12 months. This therapy led to alleviation of COPD via immunomodulatory effects and decrease of inflammation by releasing EVs and no adverse effects were detected [60]. One placebo-controlled, randomized clinical trial investigated the safety and the effect of allogeneic BM-MSCs for severe COPD therapy in 62 individuals between 40 to 80 years enrolled from different institutions in the United States; http://clinicaltrials.gov, NCT00683722. The participants received four monthly administrations ($10^6$ cells/per infusion) and no deaths or serious adverse events were found during the 2-year follow-up period. Besides, the serum levels of circulating CRP was significantly reduced in patients received MSCs therapy at study entry. Nevertheless,
no considerable enhancement was observed in COPD patients who received MSC treatment [61]. Moreover, a randomized clinical article by these authors have also published in 2021 to evaluate the impact of allogenic BM-MSC transplantation in 62 COPD patients with high levels of CRP (NCT00683722). In contrast with the results of previous study, they showed significant efficiency of BM-MSCs in pulmonary function improvements [62].

**Asthma**

An experimental study by Mohammadian et al. in 2018 demonstrated that a single infusion of simvastatin in combination with BM-MSCs could remarkably reduce serum total and specific IgE, as well as lung IL-13 and TGF-β levels in ovalbumin-induced murine models of asthma as compared with simvastatin alone. The excellent effects of combination therapy may be because of elevation of BM-MSC migration to lung [63]. In another work, immunoregulatory effects of BM-MSCs and mitochondrial signaling pathways was investigated in asthmatic mice model through both intratracheal and systemic routs. The authors proposed that BM-MSC therapy is a potential strategy in preventing lung damage through suppressing the eosinophils, inflammatory cytokines, mucus hyper-production and the mitochondria genes expression, but increasing IFN-γ. However, there were some drawbacks including not studying the BM-MSCs on chronic lung inflammation and asthma and also remodeling associated biofactors were not done [64]. Abreu and coworkers (2017) compared the therapeutic efficiency of intratracheal injection of MSCs derived from BM, AD, and lung in ovalbumin-induced mice model of asthma. Their result showed that BM-MSCs are more potent in decrease of inflammatory cytokines, eosinophils, and VEGF in lung in comparison with AD- and lung-MSCs. Furthermore, only BM-MSCs were able to increase IL-10 and IFN-γ in lung. Results of in vitro study also showed that BM-MSCs augmented polarization of macrophages toward M2. More researches are needed for evaluation of various MSCs potential in phagocytosing macrophages differentially. Whereas, MSCs from AD and lung had higher baseline levels of IL-4, insulin-like growth factor (IGF), and VEGF secretion [65]. It has also been evidenced that intratracheal administration of rat BM-MSCs and conditioned media (CM) have potential role in improving pathological changes in ovalbumin-sensitized asthmatic rats probably through modulating ICAM-1 and VCAM-1 expression in lung tissues. Results also represented that rat BM-MSCs pose more regenerative abilities than that of CM. However, there were several restrictions regarding this study such as not investigation of ICAM-1 and VCAM-1 expression on circulating leukocytes and not measuring of protein levels of both molecules and signaling pathways at the downstream. Furthermore, the content of CM was not examined completely and it is better to address the presence of modulating factors in the future studies [66]. Another research conducted by Işık et al. (2016) proved that BM-MSC administration via intraperitoneal route could ameliorate ovalbumin-induced allergic rhinitis in the murine model through migrating to lung and nasal tissues. They proposed that the BM-MSCs enhanced to the airway remodeling and inflammation through the downregulation of Th2 cells [67]. It has also been indicated that prevention of Notch1/ligand pathway improve BM-MSC homing to enhance asthma in rats through regulating Th1/Th2 drift [68]. The therapeutic effect of BM-MSCs have also been assessed in ovalbumin-induced allergic asthma and cytokine responses in mice. The authors found that the BM-MSCs could considerably decrease the total cells, eosinophilia and serum IgE secretion by inhibiting Th2 and Th17 cytokines and elevating of Treg cytokines concentration [69]. In addition, BM-MSCs have shown immunosuppressive effects on asthma, that is mediated by TGF-β-signaling-dependent alveolar macrophage polarization [70]. Furthermore, it was found by Goldstein et al. that human BM-MSCs are able to decrease chronic inflammation in an ovalbumin-induced murine asthma model through decreasing extracellular matrix (ECM) deposition as evidenced by reductions in soluble and insoluble collagen synthesis [71].

**Induced-pluripotent stem cell-MSCs**

**COPD**

In a report by Li et al. [72], iPSC-MSCs were intravenously administrated into the mice with pulmonary obstruction exposed to ozone. According to the results, a remarkable reduction was observed in oxidative stress-induced mitochondrial dysfunction as well as decreased in airway inflammation and airway hyper-responsiveness (AHR) in the murine lungs. Moreover, in vitro results showed that human airway smooth muscle cells (ASMCs)-treated iPSC-MSCs significantly downregulate mitochondrial reactive oxygen species (ROS) and apoptosis in these cells. Nevertheless, the in vitro and in vivo models did not indicate the condition in COPD lungs. Moreover, in the lack of CS, iPSC-MSCs augmented ASMCs apoptosis probably by inducing stress in these cells at baseline, implying that the safety of the MSCs must be carefully analyzed.

**Asthma**

A recent finding has demonstrated that intranasal administration of iPSC- and mesenchymoangioblast-derived MSCs provided superior protection against
ovalbumin-induced chronic allergic airways disease/asthma than that of clinically used corticosteroid [73].

**Wharton’s jelly-MSCs**

*COPD*

Park et al. (2018) evaluated the therapeutic efficiency of WJ-MSCs in treatment of two mouse emphysema models, an elastase-induced and a CS-induced models [74]. The authors demonstrated that intravenous administration of pioglitazone pretreated WJ-MSCs ($10^4$ cells) led to better pulmonary regeneration as compared with non-treated cells. In a similar study, Cho and coworkers [75] have investigated the efficiency of WJ-MSC therapy for lung recovery in COPD murine models. The mice were divided into three groups including sham group that was not induced COPD, nor received any therapy, COPD mice received saline as controls, and COPD mice received WJ-MSCs ($5 \times 10^4$ cells) intravenously. Authors declared that no significant effects of WJ-MSC therapy was found in this experiment that may be related to the low number of animals. Another drawback of this study was that no mechanism underlying the effect of WJ-MSCs was not identified.

**Human cord blood-MSCs**

*COPD*

In a study conducted by You-Sun Kim et al. [76], systemic injection of hCB-MSCs into a CS-induced COPD mouse model, were shown to have regenerative effects based on the gene expression profile changes. According to the results of this study, immune responses, oxidative stress, and transcription were regulated in the lung cells on days 1 and 4 after hCB-MSC administration, whereas blood vessel growth were regulated at a later stage (on day 14) in comparison with controls. However, there is a lack of mice group exposed to normal air to exact identification of regeneration mechanisms of hCB-MSCs. In addition, their microarray experiment utilized whole lungs and therefore, gene profiles change in individual cells remained uncertain.

**Asthma**

Shin et al. assessed the beneficial effects of hUC-MSC therapy in two murine models of severe asthma, which ameliorated via suppressing inflammation through Th2 lymphocytes. Moreover, in vitro results indicated that hUC-MSCs directly reduced the IL-5 and IL-13 levels of differentiated mouse Th2 lymphocytes and peripheral blood mononuclear cells (PBMC) from asthmatic patients [77].

**Umbilical cord-MSCs**

*COPD*

Hoang et al. (2021) performed a matched case–control phase I/II trial involving 40 patients with mild-to-severe COPD at Vinmec Times City International Hospital, Hanoi, Vietnam (NCT04433104). Twenty patients were intravenously administrated twice by UC-MSCs as intervention therapy with an interval of three months and at a dose of $10^6$ cells/kg. Twenty other participants were also recruited as control group and followed up for one year. This study provided data supporting that UC-MSC therapy is a safe and efficient treatment for COPD patients. However, it was not conducted as a randomized trial which is a drawback of this study [78]. Likewise, Bich and coworkers published a pilot clinical study registered in ISRCTN with a registration number of ISRCTN70443938 which explored the safety and efficiency of allogeneic UC-MSCs in 20 patients suffering from mild-to-severe COPD [79]. A single dose of UC-MSCs ($10^6$ cells/kg) were injected to the participants and followed for 6 months. No severe adverse effects or mortality were happened that were deemed correlated with UC-MSC infusion. Moreover, the treated patients displayed a considerably decreased Modified Medical Research Council score, COPD assessment test, and number of exacerbations. Nevertheless, CRP and the FEV in 1 s (FEV1) were not showed any significant reduction in these patients after therapy in comparison with those before the treatment.

**Adipose tissue-MSCs**

*COPD*

A more recent publication in 2021 confirmed the therapeutic potential of MSC therapy in COPD patients (NCT02412332). In this randomized, open-controlled phase I clinical trial, 20 participants suffering from grade 3 COPD were recruited from pulmonology outpatient clinic of Faculdade de Medicina ABC (ABC Medical School, Brazil) and Instituto Chico Anysio (Rio de Janeiro, Brazil) and divided to four groups: 1. five individuals received conventional therapy, 2. five individuals received BM-MCs, 3. five individuals received adipose-derived (AD)-MSCs, and 4. five individuals received the co-administration of BM-MCs and AD-MSCs. No side effects linked to MSC therapy was detected after one-year follow-up. The BM-MC-derived patients indicated elevated FEV1 and diffusing capacity for carbon monoxide (DLCO). Besides, the co-administrated group demonstrated DLCO and better life quality [80].
**Asthma**

Results of an experimental research indicated that AD-MSCs and BM-MSCs could suppress AHR and airway inflammation in ovalbumin-induced mice. Nevertheless, double MSC therapy considerably induced eosinophilic airway inflammation and lung histological alterations and then, it is not effective against asthma [81]. The beneficial effects of AD-MSCs have also evaluated in ovalbumin-sensitized asthmatic murine model. Intratracheal injection of these MSCs relieved airway inflammation, AHR and enhanced airway remodeling which may be related to the regulation of Th1/Th2 cell balance [17]. Since dust mite or Alternaria animal models display a closer similarity to human asthma, it’s better to analyze the therapeutic effects of MSCs in these models in studies. For example, Castro et al. (2020) have highlighted the therapeutic impacts of multiple-dose human AD-MSCs injected systemically in an experimental model of house dust mite-induced allergic asthma which attenuated pulmonary inflammation and remodeling but contributing to immunosuppression [82]. In 2016, a pilot study by Trzil et al. was also conducted to investigate the feasibility and efficacy of five intravenous administrations of AD-MSCs in an experimental feline asthma model. They proposed that the AD-MSCs could have a delayed potential in decreasing airway inflammation, AHR and remodeling [83].

**Human amniotic membrane-MSCs**

**Asthma**

As shown by Dalouchi et al. (2021) in their article, hAM-MSC-CM notably modulated fibrosis, oxidative stress, and inflammation via decreasing the level of eosinophils and neutrophils, IL-4, and TGF-β in ovalbumin-induced asthma murine model. The results also indicated that the MSC-CM elevated the IFN-γ and IL-10 [84].

**Human placental-MSCs**

**Asthma**

With an ovalbumin-induced rat model of acute asthma, injection of hP-MSCs exerted beneficial effects on asthmatic rats and suppressed inflammation by modulating Notch signaling pathway [85]. Besides, the results of this study showed that serum IFN-γ notably elevated after hP-MSCs transplantation, whereas IL-4 and IgE reduced. Another in vitro study indicated that hP-MSCs could attenuate the proliferation and activation of CD4+ and CD8+ T cells and decreased IL-5 level in culture in different subgroups of children with asthma. However, this study was performed on small number of children and only analyzed IL-5 [86]. Another animal study by Li and coworkers [87] revealed that Th17/Treg balance were regulated following hP-MSC administration and improved AHR and inflammation in ovalbumin-induced asthmatic rats.

**Dental follicle-MSCs**

**Asthma**

In an in vitro study by Genç et al. (2018), the immunoregulatory potential of DF-MSCs was investigated through isolating PBMCs from healthy and asthmatic patients. They found that the DF-MSCs suppressed Th2 mediated immune responses and IL-4 cytokine and elevated Tregs and IFN-γ level [88]. Furthermore, it was indicated that the DF-MSCs decreased inflammation by IDO and TGF-β pathways in asthmatic patients.

**Various MSC-EVs in treatment of COPD and asthma**

Table 1 also summarized the studies employed various MSC-EVs in treatment of COPD and asthma disorders which are discussed in the following parts.

**Bone marrow-MSC-EVs**

**COPD**

The therapeutic effects of intraperitoneal co-administration of BM-MSCs and BM-MSC-Exos was examined by Maremanda et al. [89] in CS-induced mitochondrial dysfunction in COPD mouse. According to the findings of this study, the combination therapy alleviated COPD through anti-inflammatory and targeting mitochondrial genes and indicated protection in comparison with BM-MSCs or their exosomes alone.

**Asthma**

In a research, the immunomodulatory impacts of BM-MSC-Exos evaluated on PBMCs of patients suffering from asthma. Obtained data elucidated that the MSC-Exos increase IL-10 and TGF-β1 from PBMCs, therefore improving proliferation and immunomodulation capability of Treg cells [90]. In addition, Song and coworkers showed that administration of BM-MSCs and BM-MSC-Exos into the ovalbumin-induced asthma rat model could notably prevent chronic airway inflammation, decrease remodeling and EMT in the lung epithelial cells via suppressing Wnt/β-catenin signaling pathway [91]. It has also been recently shown that exosomal miR-188 from BM-MSC-derived exosomes could attenuate proliferation of bronchial smooth muscle cells and pulmonary damage in asthmatic ovalbumin-induced murine models by the JARID2/Wnt/β-catenin axis. Besides, the exosomes considerably decreased the abnormal proliferation and migration of TGF-β1-tread bronchial smooth muscle cells in vitro [92]. Zhou et al. (2021), also found that exosomal miR-146a-5p released from BM-MSCs could prevent the Th2 cells differentiation by regulating
the SERPINB2 pathway in the blood sample of allergic rhinitis patients [93].

**Adipose tissue-MSC-EVs**

**Asthma**

A recent research from Mun et al. [94] discovered that intranasal injection of AD-MSC-EVs have immunoregulatory impacts in a murine model of ovalbumin-induced asthma via attenuating AHR and inflammatory responses caused by the induction of Tregs. However, they could not differentiate if these effects were associated with exosomes, microvesicles, or a combination of these. In an experiment by Feng et al. [95], the therapeutic potential of AD-MSC-Exo-derived miR-301a-3p was investigated in ovalbumin-induced asthma murine model. They reported that the exosomes were efficiently internalized by airway smooth muscle cells and their secreted miR-301a-3p significantly down-regulated the inflammation, platelet-derived growth factor-BB (PDGF-BB), stimulated proliferation and migration and increased apoptosis in these cells through targeting STAT3. Furthermore, systemic administration of AD-MSC-EVs are associated with reduction of fibrosis and eosinophil counts in lung tissue and airway remodeling, however, their impacts on T cells differed in lung and thymus of allergic asthma ovalbumin mouse model. Nonetheless, AD-MSCs or EVs were not tracked following injection and therefore limited knowledge concerning their delivery and homing. Besides, the efficiency of only a single dose was investigated that is another limitation of this study [96]. Another animal study showed that exosomes from mmu_circ_0001359-modified AD-MSCs could significantly attenuate airway remodeling by improving FoxO1 signaling-mediated M2-like macrophage activation, by sponging miR-183-5p [97].

**Induced-pluripotent stem cell-MSC-EVs**

**Asthma**

Fang and coworkers [98] declared that small EV-miR-146a-5p from human iPSC-MSCs could inhibit group 2 innate lymphoid cell (ILC2)-dominant allergic airway inflammation in mouse model and in vitro.

**Human umbilical cord-MSC-EVs**

**Asthma**

Dong et al. administrated EVs released from Nor- and Hypoxic-hUC-MSCs to two groups of ovalbumin-induced mice models of chronic allergic asthma. The control group was also received PBS. They found that Hypo-EV-treated group were more significantly potent in suppression of the pro-inflammatory cytokines such as IL-4 and IL-13, and eosinophils and attenuating airway remodeling via decreasing expression of pro-fibrogenic markers than that of Nor-EVs. Additionally, it was demonstrated that miR-146a-5p enriched in Hypo-EVs could mediate lung protection in ovalbumin mice. These alternations may contribute to enhanced outcomes for hUC-MSC-EVs related to inhibition of TGF-β1/Smad2/3 signaling pathway and protection of airway inflammation and fibrosis [99]. It has been demonstrated that intratracheal infusion of hUC-MSC-Exos into severe steroid-resistant asthma (SSRA) mice suppress airway inflammation and AHR. In vitro results of this study also reported that these exosomes could upregulate M1 polarization to M2 in LPS-stimulated RAW 264.7 cells and the underlying mechanism may be modulating the activation of NF-kB and PI3K/AKT signaling through targeting TRAF1 [100].

**Placental-MSC-EVs**

**COPD**

For example, in an animal study conducted by Harrell et al., molecular and cellular mechanisms of P-MSC-Exo-derived multiple allogeneic protein paracrine signaling (MAPPS) was evaluated in CS-exposed mice models of COPD. The P-MSC-Exo-MAPPS considerably enhanced pulmonary function through decreasing serum concentrations of inflammatory cytokines (TNF-α, IL-1β, IL-12, and IFN-γ), lung-infiltrated macrophages, neutrophils and their secreted serine proteases, and natural killer and antigen-presenting cells. In addition, these products elevated anti-inflammatory IL-10 and regulatory T cells (Tregs) in COPD mice. The therapeutic potential of P-MSC-Exo-MAPPS was further investigated in 30 COPD patients and no adverse effects were found. The results also showed enhanced lung status and quality of life in these individuals [101].

**Asthma**

Ren et al. [102] elucidated that twice intranasal delivery of hP-MSC-Exos could be employ as emerging therapeutic tools for the treatment of an ovalbumin-induced murine model of asthma via their immunomodulatory effects which were due to the expansion of IL-10 producing lung interstitial macrophages.

**Conclusion and future perspective**

In recent years, MSCs have gained prominent implications in treatment of different respiratory diseases with regard to their therapeutic abilities such as anti-inflammatory and immunoregulatory properties, regenerative capacity as well as many other beneficial features. Accumulating researches have been assessed the safety and efficiency of MSCs from different sources such as BM, adipose tissue, hUC, UCB, WJ, placental, etc., in COPD. Although, more clinical studies are still needed to
warrant the safety and feasibility of MSC therapy especially in asthma prior to their routine application in the clinic. Small number of recruited participants was also a prominent limitation in most of the clinical trials.

BM-MSCs were the most prevalent source employed for assessments in lung disorders. In addition, because of their lower tumorigenicity, immunogenicity, and easier management, EVs, especially exosomes, may be a safer and effective therapeutic tools for treatment of lung conditions as compared with their parental MSCs. Nevertheless, the underlying mechanism in MSC-EVs biogenesis, pharmacokinetics and biodistribution requires very extensive investigations prior to the application of this approach in clinic. Further comprehensive experiments are also required to clarify the optimal protocol for isolation and preparation of MSCs for clinical use. Furthermore, modification or engineering of MSC-derived EVs can make them emerging therapeutic candidates for decreasing undesired adverse events in the future clinical use of MSC-EVs.

Abbreviations
AHR: Airway hyper-responsiveness; ASMCs: Airway smooth muscle cells; AD: Adipose tissue; BM: Bone marrow; BM-MSCs: Bone marrow-derived mononuclear cells; COPD: Chronic obstructive pulmonary disease; cr-RSV: Cis-resveratrol; CRP: C-reactive protein; CM: Conditioned media; CS: Cigarette smoke; DLOCO: Diffusing capacity for carbon monoxide; EVs: Extracellular vesicles; ECM: Extracellular matrix; EBV: Endobronchial valves; FEV: Forced expiratory volume; HGF: Hepatocyte growth factor; Hi-PSC: Induced pluripotent stem cells; hUC: Human cord blood; hAM: Human amniotic membrane; hP: Human placental; HSP: Heat-shock protein; IGF: Insulin-like growth factor; LVRS: Volume reduction surgery; MSCs: Mesenchymal stem cells; MPs: Microparticles; MAPPS: Multiple allogeneic protein paracrine signaling; PBMC: Peripheral blood mononuclear cells; PDGF-BB: Platelet-derived growth factor-BB; ROS: Reactive oxygen species; SSRA: Severe steroid-resistant asthma; TGF-1: Transforming growth factor-β1; UCB: Umbilical cord; VEGF: Vascular endothelial growth factor; VEGFA: Vascular endothelial growth factor A; WHO: World health organization; WJ: Wharton’s Jelly.

Acknowledgements
This work has been done as part of the thesis for Hossein Abbaszadeh and supported by stem cell research center at Tabriz University of Medical Sciences, Iran.

Author contributions
HA and FGH performed and wrote the manuscript; SA, AK and HV collected the references, designed the table and figures; AN and AS modified the manuscript; and KSH, LR, MA, and FJN designed the manuscript and approved the final manuscript for publication. All authors read and approved the final manuscript.

Funding
Stem cell research center at Tabriz University of Medical Sciences, Iran, Grant/ Award Number: 68331.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors indicated no potential conflicts of interest.

Author details
1 Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Tuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran. 3 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Received: 8 March 2022   Accepted: 31 May 2022
Published online: 20 June 2022

References
1. Wang N, et al. The potential roles of exosomes in chronic obstructive pulmonary disease. Front Med. 2021;7:1095.
2. Mohan A, et al. Extracellular vesicles: novel communicators in lung diseases. Respir Res. 2020;21(1):175.
3. Hogg JC, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–53.
4. Ridzuan N, et al. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles ameliorate airway inflammation in a rat model of chronic obstructive pulmonary disease (COPD). Stem Cell Res Ther. 2021;12(1):54.
5. Celi BR, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932.
6. Hashemi SY, et al. Trends in burden of chronic obstructive pulmonary disease in Iran, 1995–2015: findings from the global burden of disease study. Arch Public Health. 2020;78(1):45.
7. Zhao D, et al. Small airway disease: A different phenotype of early stage COPD associated with biomass smoke exposure. Respirology. 2018;23(2):198–205.
8. Roffel MP, et al. mirR-223: a key regulator in the innate immune response in asthma and COPD. Front Med. 2020;7:196.
9. Olloquequi J. COVID-19 Susceptibility in chronic obstructive pulmonary disease. Eur J Clin Invest. 2020;50(10): e13382.
10. Rovina N, Koutsoukou A, Koulouris NG. Inflammation and immune response in COPD: Where do we stand? Mediat Inflamm. 2013;2013:413735.
11. Ten Hacken NH, Postma DS, Timens W. Airway remodeling and long-term decline in lung function in asthma. Curr Opin Pulm Med. 2003;9(1):9–14.
12. Aguilar FS, et al. Autologous bone marrow-derived mononuclear cell therapy in three patients with severe asthma. Stem Cell Res Ther. 2020;11(1):167.
13. Nakagome K, Nagata M. Pathogenesis of airway inflammation in bronchial asthma. Auris Nasus Larynx. 2011;38(5):555–63.
14. Mirereshadi F, et al. Unraveling the therapeutic effects of mesenchymal stem cells in asthma. Stem Cell Res Ther. 2020;11(1):400.
15. Kadota T, et al. Extracellular vesicles in chronic obstructive pulmonary disease. Int J Mol Sci. 2016;17(11):1801.
16. Antunes MA, e Lapa Silva JR, Rocco PRM. Mesenchymal stromal cell therapy in COPD: from bench to bedside. Int J Chronic Obstr Pulm Dis. 2017;12:3017–27.
17. Dai R, et al. Intratracheal administration of adipose derived mesenchymal stem cells alleviates chronic asthma in a mouse model. BMC Pulm Med. 2018;18(1):131.
18. El Omar R, et al. Umbilical cord mesenchymal stem cells: The next gold standard for mesenchymal stem cell-based therapies? Tissue Eng Part B Rev. 2014;20(5):523–44.
19. Abbaszadeh H, et al. Regenerative potential of Wharton’s jelly-derived mesenchymal stem cells: a new horizon of stem cell therapy. J Cell Physiol. 2020;235(12):9230–40.
20. Wang P, et al. Mesenchymal stem cells protect against acetaminophen hepatotoxicity by secreting regenerative cytokine hepatocyte growth factor. Stem Cell Res Ther. 2022;13(1):94.
21. Chen Y, et al. Dental-derived mesenchymal stem cell sheets: a prospective tissue engineering for regenerative medicine. Stem Cell Res Ther. 2022;13(1):38.
22. Yen BL, et al. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: gleaning insights for possible use in COVID-19. Stem Cells Transl Med. 2020;9(10):1163–73.
23. Feng B, et al. Immunosuppressive effects of mesenchymal stem cells on lung B cell gene expression in LPS-induced acute lung injury. Stem Cell Res Ther. 2020;11(1):418.
24. Wang Y-Y, Li X-Z, Wang L-B. Therapeutic implications of mesenchymal stem cells in acute lung injury/acute respiratory distress syndrome. Stem Cell Res Ther. 2013;4(3):45.
25. Abbaszadeh H, et al. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles: a novel therapeutic paradigm. J Cell Physiol. 2020;235(2):706–17.
26. Mizuta Y, et al. Exosomes from adipose tissue-derived mesenchymal stem cells ameliorate histone-induced acute lung injury by activating the PI3K/Akt pathway in endothelial cells. Stem Cell Res Ther. 2020;11(1):508.
27. O’Brien J, et al. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. 2018;9:402.
28. Guiot J, et al. Exosomal miRNAs in lung diseases: from biologic function to therapeutic targets. J Clin Med. 2019;8:1349.
29. Quan Y, et al. Exosome miR-371b-5p promotes proliferation of lung alveolar progenitor type II cells by using PTEN to orchestrate the PI3K/Akt signalling. Stem Cell Res Ther. 2017;8(1):138.
30. Fujita Y, et al. Clinical application of mesenchymal stem cell-derived extracellular vesicle-based therapeutics for inflammatory lung diseases. J Clin Med. 2018;7(10):355.
31. Pittenger MF, et al. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regener Med. 2019;4(1):22.
32. Ghorbani F, et al. Renoprotective effects of extracellular vesicles: a systematic review. Gene Rep. 2022;26:101491.
33. Murray IR, Pélault B. Q&A: Mesenchymal stem cells — where do they come from and is it important? BMC Biol. 2015;13(1):99.
34. Schneider S, et al. Adipose-derived mesenchymal stem cells from liposuction and resected fat are feasible sources for regenerative medicine. Eur J Med Res. 2017;22(1):17.
35. Aravindhan S, et al. Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature. Cancer Cell Int. 2021;21(1):158.
36. Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8(4):315–7.
37. Chamberlain G, et al. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25(11):2739–49.
38. Muhrz C, et al. Ex vivo identification and characterization of a population of CD45+CD20+CD105+CD45−mesenchymal stem cells in human bone marrow. Stem Cell Res Ther. 2015;6(1):169.
39. Ren H, et al. Comparative analysis of human mesenchymal stem cells from umbilical cord, dental pulp, and menstrual blood as sources for cell therapy. Stem Cells Int. 2016;2016:351674.
40. Chen Q-H, et al. Mesenchymal stem cells regulate the Th1/Th2/Treg cell balance partly through hepatocyte growth factor in vitro. Stem Cell Res Ther. 2020;11(1):91.
41. Detamore MS. Human umbilical cord mesenchymal stromal cells in regenerative medicine. Stem Cell Res Ther. 2013;4(6):142.
42. Rezabakhsh A, Sokullu E, Rahbarghazi R. Applications, challenges and prospects of mesenchymal stem cell exosomes in regenerative medicine. Stem Cell Res Ther. 2021;12(1):521.
43. Greenwood DW, et al. Exosomes and their roles in immune regulation and cancer. Semin Cell Dev Biol. 2015;40(1):347.
44. Borges FT, Reis LA, Schor N. Extracellular vesicles: structure, function, and potential clinical uses in renal diseases. Braz J Med Biol Res. 2013;46(10):824–30.
45. Kalra H, Drummen GP, Mathivanan S. Focus on extracellular vesicles: introducing the next small big thing. Int J Mol Sci. 2016;17(2):170.
46. Broekman W, et al. TNF-α and IL-1β-activated human mesenchymal stromal cells increase airway epithelial wound healing in vitro via activation of the epidermal growth factor receptor. Respir Res. 2016;17(1):33.
47. Liu H-M, et al. MSCs relieve lung injury of COPD mice through promoting proliferation of endogenous lung stem cells. J Huazhong Univ Sci Technol [Medical Sciences]. 2015;35(6):828–33.
48. Gu W, et al. Mesenchymal stem cells alleviate airway inflammation and emphysema in COPD through down-regulation of cyclooxygenase-2 via p38 and ERK/NFκB pathways. Sci Rep. 2015;5(1):8733.
49. Cordeiro M, et al. Mesenchymal stem cell-based HSP70 promoter-driven VEGFA induction by resveratrol alleviates elastase-induced emphysema in a mouse model. Cell Stress Chaperones. 2015;20(7):101–9.
50. Broekman W, et al. Functional characterisation of bone marrow-derived mesenchymal stromal cells from COPD patients. Eur Open. 2016;2(2):00045–2015.
51. Stolk J, et al. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013;143(5):1900–8.
52. Weiss DJ, et al. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 2013;143(5):1900–8.
53. Shrestha DS, et al. Mesenchymal stem cells increase airway epithelial wound healing in vitro via activation of the epidermal growth factor receptor. Respir Res. 2016;17(1):33.
54. Cordeiro M, et al. Mesenchymal stem cells alleviate airway inflammation and emphysema in COPD through down-regulation of cyclooxygenase-2 via p38 and ERK/NFκB pathways. Sci Rep. 2015;5(1):8733.
55. Chen Y, et al. Mesenchymal stem cell-based HSP70 promoter-driven VEGFA induction by resveratrol alleviates elastase-induced emphysema in a mouse model. Cell Stress Chaperones. 2015;20(7):101–9.
56. Weiss DJ, et al. Effect of mesenchymal stem cell infusions on lung function in COPD patients with high CRP levels. Respir Res. 2021;22(1):142.
57. Mohammadian M, et al. Simvastatin and bone marrow-derived mesenchymal stem cells (BMSCs) affects serum IgE and lung cytokines levels in sensitized mice. Cytokine. 2019;113:83–8.
58. Huang M, Mehrabi Nasab E, Athari SS. Immunoregulatory effect of mesenchymal stem cell via mitochondria signaling pathways in allergic asthma. Saudi J Biol Sci. 2021;28(12):6957–62.
59. Abreu SC, et al. Bone marrow, adipose, and lung tissue-derived mesenchymal stromal cells release different mediators and differentially affect airway and lung parenchyma in experimental asthma. Stem Cells Transl Med. 2017;6(6):1557–67.
60. Rahbarghazi R, et al. Bone marrow mesenchymal stem cells and condition media diminish inflammatory adhesion molecules of pulmonary endothelial cells in an ovalbumin-induced asthmatic rat model. Microvasc Res. 2019;121:63–70.
61. Işık S, et al. Intrapleural mesenchymal stem cell administration ameliorates allergic rhinitis in the murine model. Eur Arch Otorhinolaryngol. 2017;274(1):197–207.
62. Wang K, et al. Inhibition of the Notch1/Jagged1 pathway promotes homing of bone mesenchymal stem cells to improve asthma in rats. Int J Nanomedicine. 2019;14(1):1464–72.
63. Habibian R, Delishez N, Farshid AA. The effects of bone marrow-derived mesenchymal stem cells on ovalbumin-induced allergic asthma and cytokine responses in mice. Iran J Basic Med Sci. 2018;21(5):483–8.
70. Song X, et al. Mesenchymal stem cells alleviate experimental asthma by inducing polarization of alveolar macrophages. Inflammation. 2015;38(2):485–92.
71. Goldstein BD, et al. Chronic asthma and mesenchymal stem cells: hyaluronan and airway remodeling. J Inflamm (Lond). 2017;14:18.
72. Li X, et al. Mesenchymal stem cells alleviate oxidative stress-induced mitochondrial dysfunction in the airways. J Allergy Clin Immunol. 2018;141(5):1634–1645.e5.
73. Royce SG, et al. iPSC- and mesenchymalangioblast-derived mesenchymal stem cells provide greater protection against experimental chronic allergic airway disease compared with a clinically used corticosteroid. Fasebj J. 2019;33(5):6402–11.
74. Park JS, et al. Potential therapeutic strategy in chronic obstructive pulmonary disease using pioglitazone-augmented Wharton’s jelly-derived mesenchymal stem cells. Tuberc Respir Dis (Seoul). 2019;88(2):158–65.
75. Cho JW, Park KS, Bae JY. Effects of Wharton’s jelly-derived mesenchymal stem cells on chronic obstructive pulmonary disease. Regen Ther. 2019;11:207–11.
76. Kim YS, et al. Gene profiles in a smoke-induced COPD mouse lung model following treatment with mesenchymal stem cells. Mol Cells. 2016;39:728.
77. Shin JW, et al. Mesenchymal stem cells suppress severe asthma by directly regulating Th2 cells and type 2 innate lymphoid cells. Mol Cells. 2021;44:880–90.
78. Hoang DM, et al. Allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (COPD): study protocol for a matched case-control, phase I/II trial. BMJ Open. 2021;11(5):e045788.
79. Le Thi Bich P, et al. Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study. Stem Cell Res Ther. 2020;11(1):60.
80. Squassoni SD, et al. Autologous infusion of bone marrow and mesenchymal stromal cells in patients with chronic obstructive pulmonary disease: phase I randomized clinical trial. Int J Chron Obstruct Pulm Dis. 2021;16:3561–74.
81. Hur J, et al. Evaluation of human MSCs treatment frequency on airway inflammation in a mouse model of acute asthma. J Korean Med Sci. 2020;35(23):e188.
82. Castro LL, et al. Multiple doses of adipose tissue-derived mesenchymal stromal cells induce immunosuppression in experimental asthma. Stem Cells Transl Med. 2020;9(2):230–60.
83. Trzil JE, et al. Intranasal adipose-derived mesenchymal stem cell therapy for the treatment of feline asthma: a pilot study. J Feline Med Surg. 2016;18(12):981–90.
84. Dalouchi F, et al. Human amniotic membrane mesenchymal stem cell-conditioned medium reduces inflammatory factors and fibrosis in ovalbumin-induced asthma in mice. Exp Physiol. 2021;106(2):544–54.
85. Li Y, et al. Human placenta mesenchymal stem cells suppress airway inflammation in asthmatic rats by modulating notch signaling. Mol Med Rep. 2018;17(4):5336–43.
86. Lin SC, et al. Placenta-derived mesenchymal stem cells reduce the interleukin-5 level experimentally in children with asthma. Int J Med Sci. 2019;16(11):1430–8.
87. Li Y, et al. Placenta-derived mesenchymal stem cells improve airway hyperresponsiveness and inflammation in asthmatic rats by modulating the Th17/Treg balance. Mol Med Rep. 2017;16(6):8137–45.
88. Genç D, et al. Dental follicle mesenchymal stem cells down-regulate Th2-mediated immune response in asthmatic patients mononuclear cells. Clin Exp Allergy. 2018;48(6):663–78.
89. Maremanda KP, Sundar IK, Rahman I. Protective role of mesenchymal stem cells and mesenchymal stem cell-derived exosomes in cigarette smoke-induced mitochondrial dysfunction in mice. Toxicol Appl Pharmacol. 2019;385:114788.
90. Du YM, et al. Mesenchymal stem cell exosomes promote immunosuppression of regulatory T cells in asthma. Exp Cell Res. 2018;363(1):114–20.
91. Song J, Zhu XM, Wei QY. MSCs reduce airway remodeling in the lungs of asthmatic rats through the Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24(21):1199–211.
92. Shan L, et al. Human bone marrow-mesenchymal stem cell-derived exosomal microRNA-188 reduces bronchial smooth muscle cell proliferation in asthma through suppressing the JARID2/Wnt/β-catenin axis. Cell Cycle. 2022;21:1–16.
93. Zhou J, et al. hMSC-derived exosome inhibited Th2 cell differentiation via regulating miR-146a-Serpinb2 pathway. J Immunol Res. 2021;2021:6946532.
94. Mun SJ, et al. Intranasally administered extracellular vesicles from adipose stem cells have immunomodulatory effects in a mouse model of asthma. Stem Cells Int. 2021;2021:6866625.
95. Feng CY, et al. Adipose-derived mesenchymal stem cell-derived exosomal miR-301a-3p regulates airway smooth muscle cells during asthma by targeting STAT3. J Asthma Allergy. 2022;15:99–110.
96. de Castro LL, et al. Human adipose tissue mesenchymal stromal cells and their extracellular vesicles act differentially on lung mechanics and inflammation in experimental allergic asthma. Stem Cell Res Ther. 2017;8(1):151.
97. Shang Y, et al. Exosomes from mmu_circ_0001359-modified ADSCs attenuate airway remodeling by enhancing FoxO1-signaling-mediated M2-like macrophase activation. Mol Ther Nucleic Acids. 2020;19:951–60.
98. Fang SB, et al. Small extracellular vesicles derived from human mesenchymal stromal cells prevent group 2 innate lymphoid cell-dominant allergic airway inflammation through delivery of miR-146a-Sp. Extracellular Vesicles. 2020;9(1):1723260.
99. Dong L, et al. Hypoxic hUCMSC-derived extracellular vesicles attenuate allergic airway inflammation and airway remodeling in chronic asthma mice. Stem Cell Res Ther. 2021;12(1):4.
100. Dong B, et al. Exosomes from human umbilical cord mesenchymal stem cells attenuate the inflammation of severe steroid-resistant asthma by reshaping macrophase polarization. Stem Cell Res Ther. 2021;12(1):204.
101. Harrell CR, et al. Molecular and cellular mechanisms responsible for beneficial effects of mesenchymal stem cell-derived product “Exo-d-MAPPS” in attenuation of chronic airway inflammation. Anal Cell Pathol (Amst). 2020;2020:3153891.
102. Ren J, et al. Intranasal delivery of MSC-derived exosomes attenuates allergic asthma via expanding IL-10 producing lung interstitial macrophages in mice. Int Immunopharmacol. 2021;91:107288.